Health outcomes evaluations: estimating the impact of almotriptan in managed care settings.

OBJECTIVE

Almotriptan, a new treatment for acute migraine attacks, may improve health outcomes while reducing expenditures on drug costs and the costs associated with unwanted adverse events. This article describes the clinical, humanistic, and economic data available for almotriptan and compares these data with published data for sumatriptan, which is considered the gold standard comparator for triptans.

PATIENTS AND METHODS

Clinical trial data and published materials describing the pharmacoeconomics of sumatriptan were reviewed.

RESULTS

Formulary and prescribing decision makers consider clinical, humanistic, and economic dimensions when evaluating migraine treatments. Within those dimensions, critical elements to consider include efficacy, tolerability, health-related quality of life, patient satisfaction, productivity, medication cost, and healthcare resource use. In direct comparisons, almotriptan has demonstrated efficacy, short-term health-related quality of life, and productivity results similar to sumatriptan 50 mg. Almotriptan also has an improved tolerability profile compared with sumatriptan, including a lower incidence of drug-related adverse events, a lower incidence of chest pain, and better patient satisfaction in terms of adverse events.

CONCLUSIONS

Almotriptan and sumatriptan exhibit comparable efficacy for the treatment of acute migraine. The acquisition cost of almotriptan is lower than sumatriptan, and given its excellent tolerability profile, almotriptan may be preferred by patients for the treatment of migraine attacks.